NCT03117985 - Tracking and Exploring the Source of Viral REbound | Crick

Overview

Phylogenic analysis of viruses hosted in marker positive reservoir cells including CD32a+ CD4 T lymphocytes and rebounding viruses after treatment interruption

Study Type

INTERVENTIONAL

Allocation

NA

Purpose

BASIC_SCIENCE

Masking

NONE

Enrollment

5

Conditions

Hiv

Interventions

no drugOTHER

Stopping antiretroviral therapy

Eligibility

Sex: ALLMin age: 18 YearsMax age: 80 Years

Medical Language ↔ Plain English

Inclusion Criteria: * \- Age\>18year old * Nadir CD4\>200/mm3 * CD4/CD8 ratio\> 0.5 * Continuous antiretroviral therapy for more than 2 years * Plasma Human Immunodeficiency Virus (HIV) 1 Ribonucleic acid (RNA) \<50 copies/ml in the last 2 years * Viral Load (VL)\<20copies at inclusion * Patients who are willing to participate and who understand the trial (particularly, the obligation to have protected intercourse during the study). * Informed consent * Short half-life treatment * Health insurance * A subset of CD4 (T4cells) express CD32a. Exclusion Criteria: * \- Acquired Immune Deficiency Syndom (AIDS) * Pregnancy * Human immunodeficiency virus (HIV)-2 co infection * Thrombopenia * Neurological events during primary infection * Hepatitis B + (HBV+) * Hepatitis C + (HCV+) * Cancer during the last 5 years. * Life expectancy \< 12 months * Autoimmunity * Acute infectious disease in the last 60 days. * Hemoglobin\<7g/dl * Glomerular filtration \< 60ml/min * Refusing protected intercourse * Risk of HIV transmission * Psychiatric disorders. * Alcool and drug abuse * Involvement in another clinical trial evaluating a therapeutic. * Being under tutorship * Being deprived of liberty

Locations (1)

Chr Orleans

Orléans, France

Outcomes

Primary Outcomes

Genetic Cartography

Measuring the genetic distance between viruses contained in marker positive reservoir cells including CD32a+ CD4 T (T4cells) lymphocytes and viruses rebounding after treatment interruption. This cartography will be made when Plasma Human Immunodeficiency Virus -1 ribonucleic acid (RNA) superior or equal to 1000 copies/ml

Time frame: Week 1

Genetic Cartography

Measuring the genetic distance between viruses contained in marker positive reservoir cells including CD32a+ CD4 T (T4cells) lymphocytes and viruses rebounding after treatment interruption. This cartography will be made when Plasma Human Immunodeficiency Virus -1 ribonucleic acid (RNA) superior or equal to 1000 copies/ml

Time frame: Week 2

Genetic Cartography

Measuring the genetic distance between viruses contained in marker positive reservoir cells including CD32a+ CD4 T (T4cells) lymphocytes and viruses rebounding after treatment interruption. This cartography will be made when Plasma Human Immunodeficiency Virus -1 ribonucleic acid (RNA) superior or equal to 1000 copies/ml

Time frame: Week 3

Genetic Cartography

Measuring the genetic distance between viruses contained in marker positive reservoir cells including CD32a+ CD4 T (T4cells) lymphocytes and viruses rebounding after treatment interruption. This cartography will be made when Plasma Human Immunodeficiency Virus -1 ribonucleic acid (RNA) superior or equal to 1000 copies/ml

Time frame: Week 4

Genetic Cartography

Measuring the genetic distance between viruses contained in marker positive reservoir cells including CD32a+ CD4 T (T4cells) lymphocytes and viruses rebounding after treatment interruption. This cartography will be made when Plasma Human Immunodeficiency Virus -1 ribonucleic acid (RNA) superior or equal to 1000 copies/ml

Time frame: Week 5